Inotiv (NOTV) Expected to Post Quarterly Earnings on Wednesday

Inotiv (NASDAQ:NOTV) is expected to be posting its Q3 2026 resultson Wednesday, August 5th. Analysts expect Inotiv to post earnings of ($0.47) per share and revenue of $136.6840 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Inotiv (NASDAQ:NOTV) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.30). The company had revenue of $117.65 million during the quarter, compared to the consensus estimate of $124.74 million. Inotiv had a negative net margin of 17.14% and a negative return on equity of 56.77%.

Inotiv Stock Performance

Shares of Inotiv stock opened at $0.01 on Tuesday. The firm has a 50-day moving average of $0.06 and a 200-day moving average of $0.24. The stock has a market cap of $387,256.80, a PE ratio of -0.00 and a beta of 3.77. Inotiv has a 52-week low of $0.08 and a 52-week high of $2.95.

Institutional Trading of Inotiv

A number of institutional investors have recently modified their holdings of NOTV. American Century Companies Inc. grew its holdings in shares of Inotiv by 16.4% during the 2nd quarter. American Century Companies Inc. now owns 41,933 shares of the company’s stock worth $76,000 after purchasing an additional 5,894 shares in the last quarter. Marshall Wace LLP raised its stake in Inotiv by 22.6% in the second quarter. Marshall Wace LLP now owns 122,372 shares of the company’s stock valued at $223,000 after purchasing an additional 22,578 shares in the last quarter. Jane Street Group LLC acquired a new position in Inotiv in the second quarter valued at about $233,000. Balyasny Asset Management L.P. lifted its position in Inotiv by 30.3% during the second quarter. Balyasny Asset Management L.P. now owns 1,654,648 shares of the company’s stock worth $3,011,000 after purchasing an additional 384,696 shares during the period. Finally, Massar Capital Management LP grew its stake in Inotiv by 133.3% during the second quarter. Massar Capital Management LP now owns 350,000 shares of the company’s stock worth $637,000 after buying an additional 200,000 shares in the last quarter. 18.17% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Inotiv in a research note on Friday, April 10th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Inotiv has a consensus rating of “Hold” and a consensus price target of $1.50.

About Inotiv

Inotiv, Inc, formerly known as Bioanalytical Systems, Inc (NASDAQ: NOTV), is a global contract research organization (CRO) specializing in preclinical drug discovery, development and testing services. The company partners with pharmaceutical, biotech and medical device companies to advance candidate molecules through early‐stage research and safety assessment. Inotiv’s integrated platform spans in vivo and in vitro pharmacology, drug metabolism and pharmacokinetics (DMPK), toxicology, pathology and bioanalysis.

The company’s core service offerings include discovery pharmacology, safety assessment toxicology, pathology, bioanalysis and regulatory support.